


PSC and PBC – KNOW THE DIFFERENCE BETWEEN THESE TWO RARE LIVER DISEASES

Understanding the difference is crucial for proper clinical management

PSC and PBC are diseases of the bile ducts with similar names, but despite sharing certain characteristics and symptoms, they require different treatments and monitoring.

Primary Sclerosing Cholangitis (PSC)

PSC all ages can be affected



PSC affects bile ducts **INSIDE AND OUTSIDE** the liver

80% of **PSC** patients have inflammatory bowel disease



No medical treatment for **PSC**



Elevated risk of **BILE DUCT** and **COLON CANCER** with **PSC**

Primary Biliary Cholangitis (PBC)

PBC onset is mostly at middle age




PBC
10% men
90% women



PBC affects bile ducts **INSIDE** the liver

1% of **PBC** patients have inflammatory bowel disease



Medical treatments available for **PBC**



PSC Partners Seeking a Cure and PSC Support

would like to thank Professor Gideon Hirschfield and Dr. Palak Trivedi for their involvement in helping us provide a concise comparison between PSC and PBC.

Professor Gideon Hirschfield

Professor of Autoimmune Liver Disease/
Honorary Consultant Hepatologist
(Birmingham, UK)

Palak Trivedi

Academic Clinical Lecturer and Specialist
Registrar in Hepatology and Gastroenterology
(Birmingham, UK)

FEATURE	PSC <i>Primary Sclerosing Cholangitis</i>	PBC <i>Primary Biliary Cholangitis</i> (commonly still referred to as <i>Primary Biliary Cirrhosis</i>)
Site of disease involvement	Bile ducts inside and outside the liver; however in small duct PSC (10-15% of patients) only the small ducts inside the liver are affected	Small bile ducts inside the liver only
Mode of diagnosis	Usually by MRI of bile ducts. Occasionally liver biopsy or ERCP is needed	Two of the following: Raised ALP, positive disease specific antibodies (AMA), diagnostic liver biopsy
Associated with increased risk of bile duct cancer and colon cancer	Yes	No
Response to ursodeoxycholic acid (UDCA)	Improves liver blood tests in some patients; not conclusively proven to slow disease progression	Associated with improved prognosis in those individuals who respond well to UDCA
Co-existing inflammatory bowel disease (IBD)	Around 80% of patients have IBD – mostly colitis	Very rare and not characteristic; around 1%
Common symptoms in early disease	Itching, fatigue, abdominal pain, cholangitis flares	Itching, fatigue, dry eyes and mouth, abdominal pain
Gender predominance	60% men, 40% women	90% women, 10% men
Average age at diagnosis	Any age; mostly around 40 years	75% are affected in middle age (>45 years old)
Associated with excess alcohol consumption	No	No
Associated with smoking history	Most often non-smokers	Associated with a history of smoking